BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Maia Biotechnology readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Maia Biotechnology's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06908304-2297@assetmemo.bio
DTSTAMP:20261121T005740Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ateganosine (THIO): Phase 3 readout est. (NCT06908304)
DESCRIPTION:Ateganosine (THIO)\, phase 3\, Non-Small Cell Lung Cancer.\nStu
 dy: A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line T
 reatment in Advanced/Metastatic NSCLC\nEstimated primary completion: 31 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ateganosine-
 thio#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06908304
URL:https://assetmemo.bio/drug/ateganosine-thio#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05208944-2297@assetmemo.bio
DTSTAMP:20261121T005740Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ateganosine (THIO): Phase 2 readout est. (NCT05208944)
DESCRIPTION:Ateganosine (THIO)\, phase 2\, Non-Small Cell Lung Cancer.\nStu
 dy: THIO Sequenced With Cemiplimab in Advanced NSCLC\nEstimated primary co
 mpletion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ateganosine-thio#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05208944
URL:https://assetmemo.bio/drug/ateganosine-thio#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
